|Articles|October 15, 2002

BioPharm International

  • BioPharm International-10-01-2002
  • Volume 15
  • Issue 10

Biotech Will Recover!

by G. Steven Burrill, Burrill & Company Beleagured by bad news since the start of the year, biotech is barely registering a pulse on Wall Street . . . but it's hardly time to write the industry's obituary.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

about 23 years ago

FDA Launches Major CGMP Review

about 23 years ago

Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)

about 23 years ago

Process Validation: How Much to Do and When to Do It

about 23 years ago

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers

about 23 years ago

GMPs and Pharmaceutical Labeling

about 23 years ago

Survival Guide to FDA Inspections: Part 2, Conducting the Audit ? Ready or Not, Here They Come

about 23 years ago

Revolutionizing Biologics Regulation

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!